Physician profile
Robert W Smith
NPI 1396730222
$5,526.44
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,582 · 2020: $923 · 2021: $502 · 2022: $915 · 2023: $917 · 2024: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,093.25 | 2019-2024 | |
| Glaxosmithkline, LLC. | $741.91 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $706.96 | 2019-2024 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $340.63 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $296.77 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $291.45 | 2019-2022 | |
| Astellas Pharma US INC | $278.20 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $221.31 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $215.93 | 2019-2021 | |
| Amarin Pharma, INC. | $179.02 | 2019-2021 | |
| Amgen INC. | $153.08 | 2019-2022 | |
| Antares Pharma, INC. | $122.39 | 2019-2021 | |
| Lilly USA, LLC | $120.90 | 2019-2023 | Mounjaro, Trulicity |
| Biohaven Pharmaceutical Holding Company LTD. | $118.60 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $91.35 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.92 | 2019-2020 | |
| Abbott Laboratories | $66.95 | 2020-2023 | Freestyle Libre 3 |
| Allergan, INC. | $57.49 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.12 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $46.89 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $32.13 | 2021 | |
| Arbor Pharmaceuticals, INC. | $30.69 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.84 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $24.98 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $21.65 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.37 | 2019 | |
| Sumitomo Pharma America, INC. | $16.68 | 2023 | Gemtesa |
| Ibsa Pharma INC. | $15.75 | 2019 | |
| Shire North American Group INC | $15.01 | 2019 | |
| Boston Scientific Corporation | $13.17 | 2022 | |
| Assertio Therapeutics, INC. | $12.88 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.78 | 2020 | |
| Genentech USA, INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.